Literature DB >> 9837958

c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells.

N Rahimi1, W Hung, E Tremblay, R Saulnier, B Elliott.   

Abstract

Overexpression and amplification of hepatocyte growth factor (HGF) receptor (Met) have been detected in many types of human cancers, suggesting a critical role for Met in growth and development of malignant cells. However, the molecular mechanism by which Met contributes to tumorigenesis is not well known. The tyrosine kinase c-Src has been implicated as a modulator of cell proliferation, spreading, and migration; these functions are also regulated by Met. To explore whether c-Src kinase is involved in HGF-induced cell growth, a mouse mammary carcinoma cell line (SP1) that co-expresses HGF and Met and a nonmalignant epithelial cell line (Mv1Lu) that expresses Met but not HGF were used. In this study, we have shown that c-Src kinase activity is constitutively elevated in SP1 cells and is induced in response to HGF in Mv1Lu cells. In addition, c-Src kinase associates with Met following stimulation with HGF. The enhanced activity of c-Src kinase also correlates with its ability to associate with Met. Expression of a dominant negative double mutant of c-Src (SRC-RF), lacking both kinase activity (K295R) and a regulatory tyrosine residue (Y527F), in SP1 cells significantly reduced c-Src kinase activity and strongly blocked HGF-induced motility and colony growth in soft agar. In contrast, expression of the dominant negative c-Src mutant had no effect on HGF-induced cell proliferation on plastic. Taken together, our data strongly suggest that HGF-induced association of c-Src with Met and c-Src activation play a critical role in HGF-induced cell motility and anchorage-independent growth of mammary carcinomas and further support the notion that the presence of paracrine and autocrine HGF loops contributes significantly to the transformed phenotype of carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9837958     DOI: 10.1074/jbc.273.50.33714

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

2.  Leucine motif-dependent tyrosine autophosphorylation of type III receptor tyrosine kinases.

Authors:  Rosana D Meyer; Xiaofeng Qian; Hwai-Chen Guo; Nader Rahimi
Journal:  J Biol Chem       Date:  2006-01-23       Impact factor: 5.157

3.  Src regulates cell cycle protein expression and renal epithelial cell proliferation via PI3K/Akt signaling-dependent and -independent mechanisms.

Authors:  Jingping Xing; Zhu Zhang; Haiping Mao; Rick G Schnellmann; Shougang Zhuang
Journal:  Am J Physiol Renal Physiol       Date:  2008-04-23

4.  3D-QSAR study of c-Src kinase inhibitors based on docking.

Authors:  Ran Cao; Na Mi; Huabei Zhang
Journal:  J Mol Model       Date:  2009-07-17       Impact factor: 1.810

5.  A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma.

Authors:  Craig W Menges; Yibai Chen; Brooke T Mossman; Jonathan Chernoff; Anthony T Yeung; Joseph R Testa
Journal:  Genes Cancer       Date:  2010-05-01

Review 6.  Biology of MET: a double life between normal tissue repair and tumor progression.

Authors:  Iacopo Petrini
Journal:  Ann Transl Med       Date:  2015-04

7.  Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.

Authors:  Kelly L Mueller; Lauren A Hunter; Stephen P Ethier; Julie L Boerner
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Role of Src signal transduction pathways in scatter factor-mediated cellular protection.

Authors:  Saijun Fan; Qinghui Meng; John J Laterra; Eliot M Rosen
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

9.  Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.

Authors:  G E Konecny; R Glas; J Dering; K Manivong; J Qi; R S Finn; G R Yang; K-L Hong; C Ginther; B Winterhoff; G Gao; J Brugge; D J Slamon
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

10.  The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy.

Authors:  Xinjie Lu; Dong Lu; Mike Scully; Vijay Kakkar
Journal:  Perspect Medicin Chem       Date:  2008-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.